Finance

Lists
Why is DEVA down 2,47%?
Dive Deeper
DEVA:IST
Deva Holding AS
80,95 TRY
-2,47%
(-2,05) 1D
13 ოქტ, 18:10:00 GMT+3  ·   TRY
All symbols
SymbolPriceChange% Change
Generating top insights for DEVA...
Open
82,65 TRY
High
83,25 TRY
Low
80,15 TRY
Mkt. cap
16,19 მლრდ.
Avg. vol.
653,35 ათ.
Volume
306,70 ათ.
52-wk high
109,30 TRY
52-wk low
57,50 TRY
EPS
-4,21 TRY
Shares outstanding
200,02 მლნ.
No. of employees
3 ათ.
Open
82,65 TRY
High
83,25 TRY
Low
80,15 TRY
Mkt. cap
16,19 მლრდ.
Avg. vol.
653,35 ათ.
Volume
306,70 ათ.
52-wk high
109,30 TRY
52-wk low
57,50 TRY
EPS
-4,21 TRY
Shares outstanding
200,02 მლნ.
No. of employees
3 ათ.
News stories
From web sources and news partners
Profile
DEVA Holding A.Ş. is a Turkish pharmaceutical company operating since 1958. Its principal activities include the development, manufacture and marketing of human pharmaceuticals and active pharmaceutical ingredients. The company also operates in veterinary medicines, cologne, medical ampoules and food supplements. A majority stake in the company was acquired by EastPharma in 2006. DEVA Holding is listed on Borsa Istanbul, and its chairman and chief executive officer is Philipp Haas. As of 2025, the company had more than 675 products across 15 therapeutic areas. According to IQVIA data cited in its annual report, DEVA ranked third in the Turkish pharmaceutical market by unit sales in 2025, with a market share of 4.5%. Wikipedia
About Deva Holding AS
CEO-
Employees3,06 ათ.
Founded22 სექ. 1958
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in TRY
Loading Previous Earnings...
Revenue
Net income
All values in TRY
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
4,47 მლრდ.
5,49 მლრდ.
6,33 მლრდ.
6,00 მლრდ.
Cost of goods sold
3,02 მლრდ.
3,84 მლრდ.
4,10 მლრდ.
2,82 მლრდ.
Cost of revenue
3,02 მლრდ.
3,84 მლრდ.
4,10 მლრდ.
2,82 მლრდ.
Research and development expenses
264,29 მლნ.
174,34 მლნ.
361,82 მლნ.
480,63 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,30 მლრდ.
1,58 მლრდ.
1,60 მლრდ.
1,68 მლრდ.
Operating expense
1,55 მლრდ.
1,74 მლრდ.
1,93 მლრდ.
2,07 მლრდ.
Total operating expenses
4,58 მლრდ.
5,58 მლრდ.
6,03 მლრდ.
4,89 მლრდ.
Operating income
-102,14 მლნ.
-89,10 მლნ.
293,59 მლნ.
1,11 მლრდ.
Other non operating income
337,87 მლნ.
185,09 მლნ.
663,10 მლნ.
-172,42 მლნ.
EBT including unusual items
-137,34 მლნ.
-340,89 მლნ.
585,37 მლნ.
527,53 მლნ.
EBT excluding unusual items
-137,34 მლნ.
-362,51 მლნ.
586,40 მლნ.
527,53 მლნ.
Income tax expense
-116,52 მლნ.
1,00 მლრდ.
682,64 მლნ.
-86,52 მლნ.
Effective tax rate
84,84%
-294,28%
116,62%
-16,40%
Other operating expenses
-9,80 მლნ.
-11,48 მლნ.
-34,86 მლნ.
-88,91 მლნ.
Net income
-20,81 მლნ.
-1,34 მლრდ.
-97,27 მლნ.
614,05 მლნ.
Net profit margin
-0,47%
-24,48%
-1,54%
10,23%
Earnings per share
-
-
-
-
Interest and investment income
59,54 მლნ.
23,47 მლნ.
114,43 მლნ.
157,88 მლნ.
Interest expense
-617,63 მლნ.
-656,70 მლნ.
-542,37 მლნ.
-662,77 მლნ.
Net interest expenses
-558,09 მლნ.
-633,23 მლნ.
-427,95 მლნ.
-504,88 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
237,92 მლნ.
622,26 მლნ.
701,87 მლნ.
1,42 მლრდ.
Gain or loss from assets sale
-15,06 მლნ.
-15,93 მლნ.
-32,28 მლნ.
-12,59 მლნ.
AI content may include mistakes. Learn more
Google აპები